References
1. Data on file. 2. Whitepaper W113.05.
13. Anderson JM. Mechanism of inflammation and infection with implanted devices. Cardiovasc Pathol. 1993;2:33S-41S. 14. Matlage BF et al. Tissue response to implanted polymers: The significance of sample shape. J Biomed Meter Res. 1976;10:391-397. 15.Nicolau PJ. Long-Lasting and permanent fillers: Biomaterials influence over host response. Plast Reconstr Surg. 2007; 119:2271-2286. 16. Ellansé Instruction for Use. Sinclair IS Pharma Corporate. 2016. 17. Radiesse instruction for Use. Merz Aesthetics. 2016. 18. Sculptra Instruction for Use. Galderma. 2016. 19. Moers-Carpi MM, Christen MO, Delmar H, Brun P, Bodokh I, Kestemont P. European Multicenter prospective clinical study evaluating long-term safety and efficacy of the polycaprolactone –based dermal filler in nasolabial fold correction. Dermatol Surg 2021, Accepted. 20. Converset-Viethel S. A prospective, randomized, controlled, comparative, single-centre study on the safety and effectiveness of Ellansé® dermal filler for correction of age-related volume deficit in the mid-face. Internal report 2020. 21. Francisco de Melo F, Nicolau P, Piovano L, Lin SL, Baptista-Fernandes T, Martyn I King M, Camporese A, Hong K, Khattar MM, Christen MO. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé®). Clinical, Cosmetic and Investigational Dermatology 2017:10 431-440.
3. Christen MO, Vercesi.F. Polycaprolactone: Or How a Well-Known and Futuristic Polymer Has Become an Innovative Collagen-Stimulator in Aesthetics. Clin
Cosmet and Investig Dermatol 2020; 12:1-18. 4. Ellansé post market surveillance report, 2022. 5. Christen MO Ellansé safety report. 2016.
6. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg. 2013;39 (3 Pt 1):457-63. 7. Bae B, et al. Safety and long-term efficacy of forehead contouring with a polycaprolactone-based dermal filler. Dermatol Surg. 2016;42(11):1256-60. 8. Nicolau P, Marijnissen-Hofsté J. Neocollagenesis after injection of a polycaprolactone based dermal filler in a rabbit. Eur.J.Aesth Medicine and Dermatology. 2013;3:19-26. 9. Kim JA, Van Abel D. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. J Cosmet Laser Ther. 2015;17(2):99-101. 10. Galadari H, et al. A randomised, prospective, blinded, split-face, single-centre study comparing polycaprolactone to hyaluronic acid for treatment of nasolabial folds. J Cosmet Dermatol. 2015;14(1): 27-32. 11. Laeschke K. Biocompatibility of microparticles into soft tissue fillers. Semin Cutan Med Surg. 2004; 23(4):214-217. 12. Morhenn VB et al. Phagocytosis of different particulate dermal filler substances by human macrophages and skin cells. Dermatol Surg. 2002;28(6):484-490.
30 ELLANSÉ PRACTITIONER GUIDE
Made with FlippingBook interactive PDF creator